Synergetic Enhancing Effects between Platinum Nanosensitizers and Clinically Approved Stabilizing Ligands in Proton Therapy, Causing High‐Yield Double‐Strand Breaks of Plasmid DNA at Relevant Dose

Proton therapy is used to eradicate tumors in sensitive areas by targeted delivery of energy. Its effectiveness can be amplified using nanoparticles (NPs) as sensitizers, due to the production of reactive oxygen species at the NP's catalytically active surface, causing the cleavage of DNA. However, the impact of stabilizing macromolecular ligands capping the particles, needed for nanosensitizer dispersion in physiological fluids, is underexplored. Herein, ligand‐free colloidal platinum NPs (PtNPs) fabricated by scalable laser synthesis in liquids are used, which allows studying particle and ligand effects separately. PtNPs are incubated with stabilizing concentrations of the clinically approved ligands albumin, Tween, and polyethylene glycol, and irradiated with proton beams at clinically relevant doses (2 and 5 Gy). At these doses, plasmid DNA cleavage larger than 55% of clustered DNA damage is achieved. Bovine serum albumin, Tween, and polyethylene glycol on the NP surface work as double‐strand breaks (DSB) enhancers and synergetic effects occur even at low and clinically relevant particle concentrations and irradiation doses. Here, DSB enhancement by ligand‐capped PtNP even exceeds the sum of the individual ligand and particle effects. The presented fundamental correlations provide selection rules for nanosensitizer design in proton therapy.

Authors

Institutions

Publication Details

Journal
Advanced NanoBiomed Research
Published
2024-09-06
DOI
https://doi.org/10.1002/anbr.202400023
Citations
1
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.17

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Synergetic Enhancing Effects between Platinum Nanosensitizers and Clinically Approved Stabilizing Ligands in Proton Therapy, Causing High‐Yield Double‐Strand Breaks of Plasmid DNA at Relevant Dose

Carina Behrends, Christoph Rehbock, Stephan Barcikowski, Shirley K. Knauer et al.
1 citations
Advanced NanoBiomed Research
Nanoparticle-Based Drug Delivery
0.17
article

Synergetic Enhancing Effects between Platinum Nanosensitizers and Clinically Approved Stabilizing Ligands in Proton Therapy, Causing High‐Yield Double‐Strand Breaks of Plasmid DNA at Relevant Dose

Carina Behrends, Christoph Rehbock, Stephan Barcikowski, Shirley K. Knauer, Katrin Hommel, Christian Bäumer, Astrid Hensel, Sandra Zwiehoff, Ramin Rishmawi, Parisa Shakibaei, Beate Timmermann
article en
1 citations

Abstract

Proton therapy is used to eradicate tumors in sensitive areas by targeted delivery of energy. Its effectiveness can be amplified using nanoparticles (NPs) as sensitizers, due to the production of reactive oxygen species at the NP's catalytically active surface, causing the cleavage of DNA. However, the impact of stabilizing macromolecular ligands capping the particles, needed for nanosensitizer dispersion in physiological fluids, is underexplored. Herein, ligand‐free colloidal platinum NPs (PtNPs) fabricated by scalable laser synthesis in liquids are used, which allows studying particle and ligand effects separately. PtNPs are incubated with stabilizing concentrations of the clinically approved ligands albumin, Tween, and polyethylene glycol, and irradiated with proton beams at clinically relevant doses (2 and 5 Gy). At these doses, plasmid DNA cleavage larger than 55% of clustered DNA damage is achieved. Bovine serum albumin, Tween, and polyethylene glycol on the NP surface work as double‐strand breaks (DSB) enhancers and synergetic effects occur even at low and clinically relevant particle concentrations and irradiation doses. Here, DSB enhancement by ligand‐capped PtNP even exceeds the sum of the individual ligand and particle effects. The presented fundamental correlations provide selection rules for nanosensitizer design in proton therapy.

Advanced NanoBiomed ResearchVol. 4(11)
German Cancer Research Center (DE), TU Dortmund University (DE), Essen University Hospital (DE), West German Heart and Vascular Center Essen (DE), Deutsches Konsortium für Translationale Krebsforschung (DE), University of Duisburg-Essen (DE)
Universität Duisburg-Essen, Mercator Research Center Ruhr, European Regional Development Fund
Affordable and clean energy
Openalex Percentile: Top 51%
Nanoparticle-Based Drug Delivery
0.17
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.